Safety, pharmacokinetics, and antitumor properties of anlotinib, an oral multi-target tyrosine kinase inhibitor, in patients with advanced refractory solid tumors

Supporters

Support the authors with ResearchCoin

Tip RSC

Journal

Journal of Hematology & Oncology

Topics

Physics

Cancer Oncology

Medicine

Epidemiology

Internal Medicine

Show all topics

DOI

10.1186/s13045-016-0332-8

License

CC-BY

Other Formats

PDF